Kilitch Drugs (India) Limited Asset Resilience Ratio
Kilitch Drugs (India) Limited asset resilience ratio. Kilitch Drugs (India) Limited (KILITCH) has an Asset Resilience Ratio of 21.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KILITCH days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kilitch Drugs (India) Limited (2011–2025)
Asset resilience ratio of Kilitch Drugs (India) Limited from 2011 to 2025. This chart shows how Kilitch Drugs (India) Limited's Asset Resilience Ratio has changed over time. Read Kilitch Drugs (India) Limited (KILITCH) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kilitch Drugs (India) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Kilitch Drugs (India) Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs330.90 Million | 8.3% |
| Short-term Investments | Rs539.23 Million | 13.53% |
| Total Liquid Assets | Rs870.13 Million | 21.83% |
Asset Resilience Insights
- Good Liquidity Position: Kilitch Drugs (India) Limited maintains a healthy 21.83% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kilitch Drugs (India) Limited Industry Peers by Asset Resilience Ratio
Compare Kilitch Drugs (India) Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Kilitch Drugs (India) Limited Asset Resilience Ratio by Year (2011–2025)
Kilitch Drugs (India) Limited asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Kilitch Drugs (India) Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 16.77% | Rs524.66 Million ≈ $5.67 Million |
Rs3.13 Billion ≈ $33.83 Million |
-8.51pp |
| 2024-03-31 | 25.28% | Rs606.88 Million ≈ $6.56 Million |
Rs2.40 Billion ≈ $25.96 Million |
+7.30pp |
| 2023-03-31 | 17.98% | Rs394.65 Million ≈ $4.27 Million |
Rs2.20 Billion ≈ $23.74 Million |
-4.53pp |
| 2022-03-31 | 22.51% | Rs472.34 Million ≈ $5.11 Million |
Rs2.10 Billion ≈ $22.69 Million |
+4.59pp |
| 2021-03-31 | 17.92% | Rs364.00 Million ≈ $3.94 Million |
Rs2.03 Billion ≈ $21.97 Million |
-1.56pp |
| 2020-03-31 | 19.47% | Rs278.10 Million ≈ $3.01 Million |
Rs1.43 Billion ≈ $15.45 Million |
-0.31pp |
| 2019-03-31 | 19.78% | Rs284.16 Million ≈ $3.07 Million |
Rs1.44 Billion ≈ $15.54 Million |
-7.69pp |
| 2018-03-31 | 27.47% | Rs350.66 Million ≈ $3.79 Million |
Rs1.28 Billion ≈ $13.81 Million |
+2.37pp |
| 2017-03-31 | 25.09% | Rs283.30 Million ≈ $3.06 Million |
Rs1.13 Billion ≈ $12.21 Million |
+5.28pp |
| 2016-03-31 | 19.82% | Rs231.21 Million ≈ $2.50 Million |
Rs1.17 Billion ≈ $12.62 Million |
+0.35pp |
| 2015-03-31 | 19.47% | Rs246.69 Million ≈ $2.67 Million |
Rs1.27 Billion ≈ $13.71 Million |
-10.88pp |
| 2014-03-31 | 30.34% | Rs391.63 Million ≈ $4.24 Million |
Rs1.29 Billion ≈ $13.96 Million |
-48.77pp |
| 2013-03-31 | 79.11% | Rs1.08 Billion ≈ $11.71 Million |
Rs1.37 Billion ≈ $14.80 Million |
+1.34pp |
| 2012-03-31 | 77.77% | Rs1.38 Billion ≈ $14.88 Million |
Rs1.77 Billion ≈ $19.13 Million |
+77.77pp |
| 2011-03-31 | 0.00% | Rs25.00K ≈ $270.37 |
Rs1.61 Billion ≈ $17.44 Million |
-- |
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more